<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-22669" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Heart-Lung Transplantation</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tully</surname>
            <given-names>Andy</given-names>
          </name>
          <aff>UIC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Sanjeev</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nagalli</surname>
            <given-names>Shivaraj</given-names>
          </name>
          <aff>Yuma Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andy Tully declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sanjeev Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shivaraj Nagalli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>10</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-22669.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Heart-lung transplantation is a complex surgical procedure reserved for patients with end-stage heart and lung diseases that are refractory to other treatments. Indications often include conditions such as pulmonary hypertension, congenital heart defects with severe pulmonary involvement, and advanced interstitial lung disease. The procedure involves replacing both the heart and lungs with those from a single donor, offering the possibility of extended survival and improved quality of life. However, heart-lung transplantation carries significant risks, including organ rejection, infection, and complications related to immunosuppressive therapy, making it a challenging yet life-saving intervention.</p>
        <p>Clinicians participating in this course gain a comprehensive understanding of the indications, surgical techniques, and postoperative management of heart-lung transplant cases. The course enhances the clinician's ability to address psychosocial and behavioral factors that impact long-term transplant success, ultimately improving patient care and safety. Further, through this course, clinicians learn to identify and manage potential complications, apply best practices for optimizing patient outcomes, and appreciate the critical role of interprofessional collaboration in providing holistic care.&#x000a0;</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify appropriate candidates for heart-lung transplantation based on clinical, functional, and psychosocial criteria.</p></list-item><list-item><p>Assess for signs of transplant rejection and other posttransplant complications using clinical and diagnostic tools.</p></list-item><list-item><p>Differentiate between indications and contraindications for heart-lung transplantation to optimize patient selection.</p></list-item><list-item><p>Communicate&#x000a0;the importance of improving care coordination amongst the interprofessional team to enhance heart-lung transplant outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22669&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22669">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-22669.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pioneered in the 1960s and successfully implemented in the 1980s, with a declining number of candidates since the 1990s,&#x000a0;simultaneous heart and lung transplantation is only indicated for patients in the end stages of both cardiac and pulmonary failure.<xref ref-type="bibr" rid="article-22669.r1">[1]</xref> Suppose only&#x000a0;1 of the&#x000a0;2 thoracic organ systems has irreversibly failed, and the other is salvageable. In that case, most treatment centers forego dual transplants as the risk-benefit analyses suggest salvage should be attempted, and only the irreversibly failed organ should be replaced. This strategy spares the patient the cumulative risk of&#x000a0;2 simultaneous transplants, shortens their time on the waiting list,&#x000a0;and allocates more organs to more patients.<xref ref-type="bibr" rid="article-22669.r2">[2]</xref><xref ref-type="bibr" rid="article-22669.r3">[3]</xref><xref ref-type="bibr" rid="article-22669.r4">[4]</xref><xref ref-type="bibr" rid="article-22669.r3">[3]</xref>&#x000a0;Therefore, in the current era, most patients are preferentially placed as candidates for either lung transplant or advanced heart failure therapies, including mechanical circulatory support and heart transplant.&#x000a0;</p>
        <p>In 2014, the United Network for Organ Sharing initiated a critical review of its heart transplantation donor allocation policy. This review was driven by several factors, including a growing imbalance between organ availability and demand, high mortality rates among the sickest patients on the waitlist, and an increase in candidates being bridged to transplant with left ventricular assist devices. The thoracic subcommittee expanded the number of priority tiers to&#x000a0;6 in the revised allocation policy to address these concerns, allowing for more precise risk stratification and reducing the need for status exceptions. While the subcommittee considered posttransplant survival, the main goal of the new system was to reduce mortality among waitlisted patients.<xref ref-type="bibr" rid="article-22669.r5">[5]</xref></p>
        <p>
<bold>Allocation Tiers and Descriptions</bold>
</p>
        <p>
<bold>Tier 1</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Veno-arterial extracorporeal membrane oxygenation&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Nondischargeable biventricular assist device (BiVAD)</p>
          </list-item>
          <list-item>
            <p>Mechanical circulatory support (MCS) with arrhythmia</p>
          </list-item>
        </list>
        <p>
<bold>Tier 2</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Dischargeable right ventricular assist device/BiVAD</p>
          </list-item>
          <list-item>
            <p>Nondischargeable left ventricular assist devices (LVAD)</p>
          </list-item>
          <list-item>
            <p>Intraaortic balloon pump or other percutaneous MCS</p>
          </list-item>
          <list-item>
            <p>MCS with malfunction</p>
          </list-item>
        </list>
        <p>
<bold>Tier 3</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Continuous&#x000a0;intravenous (IV)&#x000a0;inotropes with hemodynamic monitoring</p>
          </list-item>
          <list-item>
            <p>30-day exception period for LVAD</p>
          </list-item>
          <list-item>
            <p>MCS with complications</p>
          </list-item>
        </list>
        <p>
<bold>Tier 4</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Continuous IV inotropes without hemodynamic monitoring</p>
          </list-item>
          <list-item>
            <p>Stable LVAD</p>
          </list-item>
          <list-item>
            <p>Congenital heart disease</p>
          </list-item>
          <list-item>
            <p>Restrictive cardiomyopathy</p>
          </list-item>
          <list-item>
            <p>Retransplantation</p>
          </list-item>
        </list>
        <p>
<bold>Tier 5</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Multiorgan transplant</p>
          </list-item>
        </list>
        <p>
<bold>Tier 6</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>All other candidates</p>
          </list-item>
        </list>
        <p>Despite the advancements in organ transplantation and donor allocation strategies, heart-lung transplantation remains a rare and complex procedure, with only about 100 new cases reported annually.<xref ref-type="bibr" rid="article-22669.r3">[3]</xref>&#x000a0;The challenges associated with patient selection, donor availability, and postoperative management necessitate a highly coordinated and multidisciplinary approach. Given the limited number of cases and stringent indications, healthcare professionals must stay informed about evolving guidelines, allocation policies, and therapeutic alternatives. This introduction aims to provide a comprehensive understanding of the unique considerations and current state of heart-lung transplantation, serving as a foundation for in-depth discussions on patient management, surgical techniques, and long-term outcomes in this niche area of transplant medicine.</p>
      </sec>
      <sec id="article-22669.s3" sec-type="Indications">
        <title>Indications</title>
        <p>Conceptually, dual organ failure requiring heart-lung transplants may be due to:</p>
        <list list-type="bullet">
          <list-item>
            <p>A primary cardiac disease leading to pulmonary failure</p>
          </list-item>
          <list-item>
            <p>A primary pulmonary disease leading to cardiac failure</p>
          </list-item>
          <list-item>
            <p>A systemic process causing both cardiac and pulmonary failure&#x000a0;<xref ref-type="bibr" rid="article-22669.r6">[6]</xref></p>
          </list-item>
        </list>
        <p>The most common indications (35%) for heart-lung transplants are congenital cardiac malformations causing Eisenmenger syndrome and secondary pulmonary arterial hypertension.<xref ref-type="bibr" rid="article-22669.r7">[7]</xref><xref ref-type="bibr" rid="article-22669.r8">[8]</xref><xref ref-type="bibr" rid="article-22669.r9">[9]</xref>&#x000a0;The secondary pulmonary disease becomes unsalvageable when the pulmonary vascular resistance remains greater than 3 to 5 Woods units despite a trial of inotropes and MCS.<xref ref-type="bibr" rid="article-22669.r8">[8]</xref><xref ref-type="bibr" rid="article-22669.r10">[10]</xref>&#x000a0;When a heart transplant alone is performed in the face of such high resistance, there is a risk of acute right heart failure.<xref ref-type="bibr" rid="article-22669.r8">[8]</xref></p>
        <p>The second most common group of indications (27%) for heart-lung transplants are primary pulmonary hypertension disorders causing right heart failure.<xref ref-type="bibr" rid="article-22669.r7">[7]</xref><xref ref-type="bibr" rid="article-22669.r8">[8]</xref>&#x000a0;The criteria for unsalvageable right heart failure&#x000a0;vary between centers, given comparable outcomes between double lung transplant and heart-lung transplant for these patients.<xref ref-type="bibr" rid="article-22669.r11">[11]</xref>&#x000a0;Most centers would consider the patient for a heart-lung transplant if cardiomegaly precluded the donor lung from fitting inside the chest or if the right heart is infarcted or fibrotic.<xref ref-type="bibr" rid="article-22669.r11">[11]</xref>&#x000a0;Patients with a systemic disease that causes both cardiac and pulmonary failure, such as cystic fibrosis, or with lifestyle factors, such as smoking, which causes both emphysema and ischemic cardiac disease, can be considered for a dual transplant.<xref ref-type="bibr" rid="article-22669.r8">[8]</xref>&#x000a0;In the case of cystic fibrosis, the newly explanted recipient heart may be used as a donor organ for another recipient in a so-called &#x0201c;domino&#x0201d; transplant.<xref ref-type="bibr" rid="article-22669.r3">[3]</xref></p>
      </sec>
      <sec id="article-22669.s4" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Many contraindications for independent lung transplantation and heart transplantation also apply to the combined operation. Active malignancy or a history of malignancy in the last&#x000a0;2 to&#x000a0;5 years is a contraindication to transplant. Active substance use disorder, uncontrolled psychiatric disorders, noncompliance, poor functional status, and poor social support are likewise contraindications to transplant surgery.<xref ref-type="bibr" rid="article-22669.r11">[11]</xref>&#x000a0;Blood-type (eg, ABO) incompatibility and a positive crossmatch are contraindications for transplant between a specific donor and recipient. Human leukocyte antigen matching cannot be performed under the ischemic time constraints imposed by current thoracic organ preservation technology. Maximum cold ischemia time for hearts and lungs is described as&#x000a0;4 to&#x000a0;6 hours and&#x000a0;6 to&#x000a0;10 hours, respectively, but the best outcomes are obtained by minimizing all ischemic time.</p>
        <p>A large mismatch of donor-recipient lung size is a contraindication to transplant. Although some discrepancy can be tolerated,&#x000a0;outside of a range of 10% above or below the recipient&#x02019;s height or weight, either atelectasis or hyperexpansion pulmonary edema may result.<xref ref-type="bibr" rid="article-22669.r1">[1]</xref><xref ref-type="bibr" rid="article-22669.r12">[12]</xref>&#x000a0;Advanced age was previously considered a contraindication to transplant, but the latest pulmonary guidelines now suggest considering the comorbidities and age on a case-by-case basis.<xref ref-type="bibr" rid="article-22669.r11">[11]</xref><xref ref-type="bibr" rid="article-22669.r13">[13]</xref></p>
        <p>A prior history of thoracic surgery was previously considered to be a contraindication to transplant, given the increased risk of blood loss from lysis of pleural and mediastinal adhesions during explantation. However, increasing technical experience and using antifibrinolytic agents have made this consideration obsolete.<xref ref-type="bibr" rid="article-22669.r11">[11]</xref>&#x000a0;Classically, serum total bilirubin levels of 2.1 mg/dL or greater were a sign of advanced pulmonary hypertension and early postoperative mortality of 58%.<xref ref-type="bibr" rid="article-22669.r14">[14]</xref>&#x000a0;Concomitant liver failure must be approached with caution and may make the patient a candidate for a combined heart-lung-liver transplant.<xref ref-type="bibr" rid="article-22669.r15">[15]</xref></p>
      </sec>
      <sec id="article-22669.s5" sec-type="Preparation">
        <title>Preparation</title>
        <p>Recipient candidates must undergo an interprofessional care team review and evaluation before being listed for transplant. In the United States, heart-lung transplant recipients are currently listed under the heart allocation system to take advantage of more favorable wait times. The European system has a separate allocation for concomitant heart-lung candidates.<xref ref-type="bibr" rid="article-22669.r11">[11]</xref>&#x000a0;The ideal timing of listing a candidate for transplant is a multifactorial decision&#x000a0;that varies by the underlying etiology of organ failure.<xref ref-type="bibr" rid="article-22669.r16">[16]</xref></p>
        <p>The local organ procurement organization should adequately evaluate the donor. Donation criteria are occasionally revised to maximize benefits in chronic international donation shortage conditions. There are now standard criteria for lung donors and expanded criteria for lung donors.<xref ref-type="bibr" rid="article-22669.r17">[17]</xref></p>
      </sec>
      <sec id="article-22669.s6" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>There are 3 different operations performed during a&#x000a0;heart-lung transplant.<xref ref-type="bibr" rid="article-22669.r18">[18]</xref>&#x000a0;&#x000a0;</p>
        <p>
<bold>Donor Procurement</bold>
</p>
        <p>The donor procurement technique varies somewhat between institutions.<xref ref-type="bibr" rid="article-22669.r19">[19]</xref>&#x000a0;Generally, after the operating surgeon performs a bronchoscopy confirming&#x000a0;adequately healthy airways, the procurement proceeds through a median sternotomy. The pericardium and bilateral pleural spaces are entered, and all anatomy is inspected. The pulmonary ligaments are divided, as are the innominate and azygos veins, allowing for mobilization of the superior and inferior venae cavae, aorta, and proximal trachea. Care is taken not to dissect the distal trachea so as not to jeopardize the blood supply. When all abdominal procurement teams and the thoracic team are ready,&#x000a0;IV heparin (approximately 300 U/kg) is administered. Prostaglandin E1 is injected into the main pulmonary artery to combat hypoxic vasoconstriction, and after a brief waiting period, the aorta is cross-clamped.</p>
        <p>Cold organ preservation solution is delivered to the heart via an aortic cannula proximal to the aortic clamp and to the lungs via a pulmonary artery cannula. The absence of aortic insufficiency is confirmed to ensure the preservation of the coronary flow solution. The left atrial appendage is amputated and allowed to drain to decompress the heart as ice saline is applied to the organs. After administration of preservation solution, the heart and lung are removed en bloc. The inferior vena cava is divided, leaving enough cuff for the liver team; the superior vena cava is divided with a more generous cuff to avoid damage to the sinoatrial node. The pericardium is separated from the diaphragm. The aorta is divided at the level of the innominate artery. The anesthesia team is asked to pull upward on the endotracheal tube, then mildly inflate the lungs and keep them inflated at low pressure as the trachea is stapled with a thoracoabdominal stapler. Some surgeons will dissect the trachea from the esophagus in the donor's chest; others perform this maneuver on the back table. The organs are then packaged for transport.<xref ref-type="bibr" rid="article-22669.r1">[1]</xref><xref ref-type="bibr" rid="article-22669.r19">[19]</xref></p>
        <p>
<bold>Recipient Explantation</bold>
</p>
        <p>The recipient explantation (cardiopneumonectomy) proceeds through a median sternotomy, with careful dissection into the pericardium and bilateral pleural spaces, especially in patients with a prior thoracic surgical history. Dissection is often complicated in patients requiring heart-lung transplants, particularly those with Eisenmenger syndrome, on account of their extensive mediastinal venous collaterals. During dissection, avoiding injury to the phrenic, vagus, and recurrent laryngeal nerves is essential. Once dissection is complete, the patient is cannulated through the aorta, superior vena cava, and inferior vena cava and is placed on cardiopulmonary bypass and cooled. The heart is resected, dividing the aorta just distal to the aortic valve and the pulmonary artery to the pulmonic valve. When the right atrium is entered to divide it, some teams will divide at the level of the atrium to leave a cuff of atrial tissue around both the superior and inferior venae cavae; however, other teams will divide at the level of the cava proper, to avoid incorporating arrhythmogenic tissue in the anastomosis.</p>
        <p>The left atrium is divided at the level of the atrioventricular groove. After the heart has been removed, the lungs are explained by clamping or stapling each mainstem bronchus and dividing the bronchi and hilar vessels distally. The lungs are then removed en bloc from the chest. The mediastinum can be prepared with the heart and lungs no longer obscuring the field. The remnant pulmonary arteries are excised, except at the ligamentum arteriosum, to provide a buffer for the recurrent laryngeal nerve. The trachea is prepared by dividing it at the level of the right mainstem bronchus. Many centers will implant the new donor hila anterior to the phrenic nerve pedicles for improved mobility to inspect the posterior mediastinum. However, some centers still implant the hila posterior to the phrenic nerve pedicles for improved exposure if reoperation is required. Whichever strategy is chosen, the dissection is completed without phrenic injury, and mediastinal hemostasis is achieved before the donor heart and lungs are implanted and again obscure the exposure.<xref ref-type="bibr" rid="article-22669.r1">[1]</xref></p>
        <p>
<bold>Recipient Implantation</bold>
</p>
        <p>The recipient implantation procedure begins with preparing the graft on the back table. Nonessential mediastinal tissue is resected, and any atrial defects in the heart are closed. The donor trachea is trimmed to the level of the first or second cartilaginous ring above the carina. Generous saline irrigation and a dedicated suction catheter&#x000a0;are used to clear the donor lungs of mucus. When all is ready, the graft is lowered into the recipient's chest and kept cold with periodic cold irrigation or cold gauze pad wrappings.</p>
        <p>The anastomoses begin with the trachea; the recipient trachea at the former level of the right mainstem is sutured to the donor trachea at the level&#x000a0;1 or&#x000a0;2 rings above the carina. Some surgeons use only running permanent sutures; others use running sutures on the membranous trachea and interrupted sutures on the cartilaginous trachea. The tracheal anastomosis is covered with nearby tissue, either lymphatic or pericardial, to give a buffer against erosion into the neighboring great vessels.</p>
        <p>Once this anastomosis is complete, the chest is irrigated to dilute potential tracheal contamination. Then, attention is turned to the blood vessels. Different surgeons prefer differing orders of anastomoses of the aorta, superior vena cava, and inferior vena cava. The prior left atrial appendage defect created as a vent during donor procurement may be used again as a vent before it is then sutured closed. Once all anastomoses are complete and the circulation is aspirated for air, attention is turned toward meticulous hemostasis. The grafts may need to be gently rotated during hemostasis to achieve adequate exposure. Finally, the patient's anticoagulation is reversed, cardiopulmonary bypass is weaned, chest tubes and pacer wires are placed, the patient's chest is closed, and the patient is brought to recover in the intensive care unit.<xref ref-type="bibr" rid="article-22669.r1">[1]</xref></p>
      </sec>
      <sec id="article-22669.s7" sec-type="Complications">
        <title>Complications</title>
        <p>Patients with a heart-lung transplant are at risk for a multitude of early complications, as would be expected after major thoracic transplant surgery. In particular, primary graft dysfunction of the lung from ischemic reperfusion injury results in increasingly severe hypercapnia and hypoxia, with an incidence of 15% to 20% after 48 to 72 hours.<xref ref-type="bibr" rid="article-22669.r17">[17]</xref>&#x000a0;Primary cardiac graft failure, defined by severe sustained hemodynamic status without alternative explanation, is another high-risk complication with an incidence of up to 22% and mortality of 53%&#x000a0;and&#x000a0;seems to be more associated with idiopathic hypertension and sarcoidosis in the recipient.<xref ref-type="bibr" rid="article-22669.r17">[17]</xref>&#x000a0;As with any tracheal surgery, the patient is at risk of acute airway emergencies, but this incidence has been reported to be reasonably low, cited to be 3.8% in 1993.<xref ref-type="bibr" rid="article-22669.r20">[20]</xref></p>
        <p>Later complications arise from the transplant conundrum of balancing immune suppression, infections, and medication adverse events against the risk of rejection. Chronic rejection of the lung graft manifested as bronchiolitis obliterans syndrome occurs in 7% and 31% of patients at&#x000a0;1 and&#x000a0;5 years, respectively.<xref ref-type="bibr" rid="article-22669.r21">[21]</xref>&#x000a0;Chronic rejection of the heart graft, manifesting as coronary artery vasculopathy, occurs in 8%.<xref ref-type="bibr" rid="article-22669.r16">[16]</xref>&#x000a0;</p>
        <p>Immunosuppression protocols and rejection surveillance with echocardiography (with endomyocardial biopsy considered if echocardiography is abnormal), surveillance bronchoscopy with endobronchial biopsy, and spirometry remain center-specific and patient-dependent.<xref ref-type="bibr" rid="article-22669.r8">[8]</xref>&#x000a0;Immune suppression must be carefully titrated because, on the other side of the balance, infection in these patients has historically caused 40% of all mortality, with fungal infections being prevalent in the first month and involved in up to 14% of infectious complications.<xref ref-type="bibr" rid="article-22669.r22">[22]</xref>&#x000a0;</p>
        <p>Medication-induced adverse events are also common in a high percentage of transplant recipients, eg, 88% with posttransplant hypertension, 70% with hyperlipidemia, 17% to 27% with diabetes, and 46% with renal dysfunction&#x02014;with 2% to 4% progressing to dialysis.<xref ref-type="bibr" rid="article-22669.r16">[16]</xref><xref ref-type="bibr" rid="article-22669.r21">[21]</xref>&#x000a0;These patients must also be monitored for posttransplant malignancies, especially posttransplant lymphoproliferative disorder, which seems to have a higher incidence of 7.6% in those with heart-lung transplant, compared to 5.4% with heart transplant alone and in the lung without heart (3.1%). This complication may occur within the first year.<xref ref-type="bibr" rid="article-22669.r8">[8]</xref>&#x000a0;There has been some enthusiastic speculation that multiorgan transplants may have an increased tendency to promote recipient tolerance to the donor organs, in contrast with a single organ transplanted alone. However, this hypothesis does not seem supported in a heart-lung transplant.<xref ref-type="bibr" rid="article-22669.r21">[21]</xref></p>
        <p>Several complications may arise from a complicated surgical dissection. Injury or excess manipulation of the vagus nerves may lead to gastroparesis, gastroesophageal reflux disease, and aspiration. These conditions can be quite adverse to the lung graft and are risk factors for bronchiolitis obliterans syndrome. Injury to the phrenic nerves may result in diaphragmatic paresis manifesting as acute to chronic dyspnea; injury to the thoracic duct may lead to chylothorax.<xref ref-type="bibr" rid="article-22669.r8">[8]</xref></p>
      </sec>
      <sec id="article-22669.s8" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Since the first successful heart-lung transplant in 1981, nearly 4000 patients have been transplanted.<xref ref-type="bibr" rid="article-22669.r8">[8]</xref>&#x000a0;With improvements in patient selection and technique, the median survival for heart-lung transplant has been increasing, from 2.1 years (1982-1993) to 3.7 years (1994-2003), to 5.8 years (2004-2016).<xref ref-type="bibr" rid="article-22669.r21">[21]</xref>&#x000a0;After the first year postoperatively, survivors can expect a median survival of 10.3 years. One high-volume center (n= 34 over a decade)&#x000a0;has reported&#x000a0;survival rates of 82%, 69%, 62%, 54%, and 54% at 1, 3, 5, 10, and 15 years, respectively.<xref ref-type="bibr" rid="article-22669.r16">[16]</xref></p>
        <p>This median survival must be seen in the context of patients who are critically ill with dual organ failure, for whom any survival without transplant is virtually unthinkable. Many of these patients are young and would otherwise be in the prime of life; 68% to 78% are younger than 50, and 30% to 35% are between 18 and 34 in North America and Europe, respectively.<xref ref-type="bibr" rid="article-22669.r21">[21]</xref>&#x000a0;With improving care for children with congenital cardiac anomalies, survivorship to adulthood is now 75% to 85%. But with longevity comes wear and tear on even the most durable repair of an anomalous circulation; up to 10% to 20% of these patients will still require a transplant in their lifetimes.<xref ref-type="bibr" rid="article-22669.r16">[16]</xref>&#x000a0;Heart-lung transplantation provides a valuable extension for quality years of life.<xref ref-type="bibr" rid="article-22669.r23">[23]</xref></p>
      </sec>
      <sec id="article-22669.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A heart-lung transplant, as a highly complex and life-altering intervention, demands the coordinated efforts of a dynamic, multifaceted team. This team typically includes surgeons, cardiologists, pulmonologists, anesthesiologists, nurses, transplant pharmacists, physical and occupational therapists, respiratory therapists, dietitians, social workers, and clinical psychologists. Each healthcare professional plays a critical role, from preoperative assessments to postoperative care. Effective collaboration and interprofessional communication are crucial to ensuring patient-centered care, minimizing complications, and improving long-term outcomes. For instance, pharmacists ensure proper immunosuppressive therapy, while dietitians and therapists promote recovery and physical function. Social workers and psychologists help address psychosocial, behavioral, and demographic factors, which are increasingly recognized as important for long-term transplant success.<xref ref-type="bibr" rid="article-22669.r24">[24]</xref></p>
        <p>Care coordination among team members is pivotal in navigating the intricate transplant process, where even minor miscommunications can lead to adverse outcomes. Psychosocial, demographic, and behavioral factors are now recognized as significant determinants of long-term survival in transplant recipients.<xref ref-type="bibr" rid="article-22669.r25">[25]</xref> Thus, the team must work closely with patients and their families, offering education and support to ensure adherence to posttransplant care plans and lifestyle modifications. This collaborative approach enhances patient-centered care, improves long-term outcomes, and promotes team performance, ensuring patients receive the highest standard of care throughout their transplant journey.</p>
      </sec>
      <sec id="article-22669.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=22669&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=22669">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/22669/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=22669">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-22669.s11">
        <title>References</title>
        <ref id="article-22669.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huddleston</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Richey</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Heart-lung transplantation.</article-title>
            <source>J Thorac Dis</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>6</volume>
            <issue>8</issue>
            <fpage>1150</fpage>
            <page-range>1150-8</page-range>
            <pub-id pub-id-type="pmid">25132983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Choong</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Sweet</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Guthrie</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Mendeloff</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Haddad</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>De La Morena</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huddleston</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Repair of congenital heart lesions combined with lung transplantation for the treatment of severe pulmonary hypertension: a 13-year experience.</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>129</volume>
            <issue>3</issue>
            <fpage>661</fpage>
            <page-range>661-9</page-range>
            <pub-id pub-id-type="pmid">15746752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hayes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Galantowicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Combined heart-lung transplantation: a perspective on the past and the future.</article-title>
            <source>Pediatr Cardiol</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>207</fpage>
            <page-range>207-12</page-range>
            <pub-id pub-id-type="pmid">22684192</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huddleston</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Commentary: Heart-lung transplantation-is it worth it?</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2024</year>
            <month>Aug</month>
            <volume>168</volume>
            <issue>2</issue>
            <fpage>595</fpage>
            <page-range>595-596</page-range>
            <pub-id pub-id-type="pmid">38423502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Truby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Farr</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Topkara</surname>
                <given-names>VK</given-names>
              </name>
            </person-group>
            <article-title>Critically appraising the 2018 United Network for Organ Sharing donor allocation policy: adding life boats or rearranging the deck chairs?</article-title>
            <source>Curr Opin Anaesthesiol</source>
            <year>2022</year>
            <month>Feb</month>
            <day>01</day>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <page-range>42-47</page-range>
            <pub-id pub-id-type="pmid">34772845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stern</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Selby</surname>
                <given-names>VN</given-names>
              </name>
              <name>
                <surname>Kolaitis</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Boin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Aras</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>De Marco</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Heart-lung transplantation: A viable option for connective tissue diseases.</article-title>
            <source>Clin Transplant</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>34</volume>
            <issue>2</issue>
            <fpage>e13776</fpage>
            <pub-id pub-id-type="pmid">31867763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trulock</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Christie</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Boucek</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Aurora</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Dobbels</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rahmel</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Keck</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Hertz</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>8</issue>
            <fpage>782</fpage>
            <page-range>782-95</page-range>
            <pub-id pub-id-type="pmid">17692782</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pasupneti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dhillon</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Reitz</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Khush</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Combined Heart Lung Transplantation: An Updated Review of the Current Literature.</article-title>
            <source>Transplantation</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>101</volume>
            <issue>10</issue>
            <fpage>2297</fpage>
            <page-range>2297-2302</page-range>
            <pub-id pub-id-type="pmid">28505026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carvajal</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Costello</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Eghtesady</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nath</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Pediatric heart-lung transplantation: Technique and special considerations.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>41</volume>
            <issue>3</issue>
            <fpage>271</fpage>
            <page-range>271-278</page-range>
            <pub-id pub-id-type="pmid">34991964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehra</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Canter</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Hannan</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Semigran</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Uber</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Baran</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Danziger-Isakov</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kirklin</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Kirk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kushwaha</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Potena</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>DO</given-names>
              </name>
              <name>
                <surname>Verschuuren</surname>
                <given-names>EAM</given-names>
              </name>
              <name>
                <surname>Zuckermann</surname>
                <given-names>A</given-names>
              </name>
              <collab>International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils</collab>
            </person-group>
            <article-title>The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>35</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-23</page-range>
            <pub-id pub-id-type="pmid">26776864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weill</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Benden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Corris</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Dark</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Keshavjee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lederer</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Mulligan</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Singer</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Snell</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Verleden</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Zamora</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Glanville</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>A consensus document for the selection of lung transplant candidates: 2014--an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>34</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-15</page-range>
            <pub-id pub-id-type="pmid">25085497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mason</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Batizy</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nowicki</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Murthy</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>McNeill</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Budev</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Pettersson</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Blackstone</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <article-title>Matching donor to recipient in lung transplantation: How much does size matter?</article-title>
            <source>J Thorac Cardiovasc Surg</source>
            <year>2009</year>
            <month>May</month>
            <volume>137</volume>
            <issue>5</issue>
            <fpage>1234</fpage>
            <page-range>1234-40.e1</page-range>
            <pub-id pub-id-type="pmid">19379997</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kwon</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Shorbaji</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Huckaby</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Welch</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hashmi</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Gibney</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Bostock</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Kilic</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Risk of recipient age on 1-year mortality after simultaneous heart-lung transplantation.</article-title>
            <source>J Card Surg</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>12</issue>
            <fpage>4437</fpage>
            <page-range>4437-4445</page-range>
            <pub-id pub-id-type="pmid">36217989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kramer</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Tiroke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lewiston</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Starnes</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Theodore</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical significance of hyperbilirubinemia in patients with pulmonary hypertension undergoing heart-lung transplantation.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>1991</year>
            <season>Mar-Apr</season>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>317</fpage>
            <page-range>317-21</page-range>
            <pub-id pub-id-type="pmid">2031931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Praseedom</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>McNeil</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Watson</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Calne</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Wallwork</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Friend</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Combined transplantation of the heart, lung, and liver.</article-title>
            <source>Lancet</source>
            <year>2001</year>
            <month>Sep</month>
            <day>08</day>
            <volume>358</volume>
            <issue>9284</issue>
            <fpage>812</fpage>
            <page-range>812-3</page-range>
            <pub-id pub-id-type="pmid">11564492</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Idrees</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Pettersson</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>State of the Art of Combined Heart-Lung Transplantation for Advanced Cardiac and Pulmonary Dysfunction.</article-title>
            <source>Curr Cardiol Rep</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>36</fpage>
            <pub-id pub-id-type="pmid">26922590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braithwaite</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>van der Kaaij</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>New Techniques for Optimization of Donor Lungs/Hearts.</article-title>
            <source>Anesthesiol Clin</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>639</fpage>
            <page-range>639-660</page-range>
            <pub-id pub-id-type="pmid">31677683</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ju</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Je</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Technical Aspects of Combined Heart-Lung Transplantation.</article-title>
            <source>J Chest Surg</source>
            <year>2022</year>
            <month>Aug</month>
            <day>05</day>
            <volume>55</volume>
            <issue>4</issue>
            <fpage>319</fpage>
            <page-range>319-324</page-range>
            <pub-id pub-id-type="pmid">35924540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Copeland</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Copeland</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hayanga</surname>
                <given-names>JWA</given-names>
              </name>
            </person-group>
            <article-title>Cardiac and pulmonary donor procurement.</article-title>
            <source>Curr Opin Organ Transplant</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>281</fpage>
            <page-range>281-285</page-range>
            <pub-id pub-id-type="pmid">29697460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shumway</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Hertz</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Maynard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kshettry</surname>
                <given-names>VR</given-names>
              </name>
              <name>
                <surname>Bolman</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Airway complications after lung and heart-lung transplantation.</article-title>
            <source>Transplant Proc</source>
            <year>1993</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>1 Pt 2</issue>
            <fpage>1165</fpage>
            <page-range>1165-6</page-range>
            <pub-id pub-id-type="pmid">8442073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chambers</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Cherikh</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Goldfarb</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Hayes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kucheryavaya</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Toll</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Khush</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Levvey</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Meiser</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rossano</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Stehlik</surname>
                <given-names>J</given-names>
              </name>
              <collab>International Society for Heart and Lung Transplantation</collab>
            </person-group>
            <article-title>The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth adult lung and heart-lung transplant report-2018; Focus theme: Multiorgan Transplantation.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>10</issue>
            <fpage>1169</fpage>
            <page-range>1169-1183</page-range>
            <pub-id pub-id-type="pmid">30293613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kramer</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Starnes</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Gamberg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Amitai</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Theodore</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Infectious complications in heart-lung transplantation. Analysis of 200 episodes.</article-title>
            <source>Arch Intern Med</source>
            <year>1993</year>
            <month>Sep</month>
            <day>13</day>
            <volume>153</volume>
            <issue>17</issue>
            <fpage>2010</fpage>
            <page-range>2010-6</page-range>
            <pub-id pub-id-type="pmid">8357286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Treffalls</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bilgili</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Sharaf</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Griffeth</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Pennington</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Villavicencio</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Daly</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Saddoughi</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Procurement Trends, Indications, and Outcomes of Heart-Lung Transplantation in the Contemporary Era.</article-title>
            <source>Clin Transplant</source>
            <year>2024</year>
            <month>Sep</month>
            <volume>38</volume>
            <issue>9</issue>
            <fpage>e15447</fpage>
            <pub-id pub-id-type="pmid">39225590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holm</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Fedson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Courtwright</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Olland</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bryce</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kanwar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sweet</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Egan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lavee</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>International society for heart and lung transplantation statement on transplant ethics.</article-title>
            <source>J Heart Lung Transplant</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>41</volume>
            <issue>10</issue>
            <fpage>1307</fpage>
            <page-range>1307-1308</page-range>
            <pub-id pub-id-type="pmid">35871113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-22669.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farmer</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Grady</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>McGee</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Cotts</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>McCarthy</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Demographic, psychosocial, and behavioral factors associated with survival after heart transplantation.</article-title>
            <source>Ann Thorac Surg</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>95</volume>
            <issue>3</issue>
            <fpage>876</fpage>
            <page-range>876-83</page-range>
            <pub-id pub-id-type="pmid">23374446</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
